PubVisualPubVisual Book a Demo
Resources Blog About Contact Book a 30-Minute Demo →
HEOR & Value Stories

Your real world evidence is strong. The dossier nobody opens is not.

The evidence took years and millions. Then it travels as a document a payer skims once, built in one fixed order that fits nobody’s actual question. The fix is not a shorter dossier. It is a value story each stakeholder can navigate their own way.

The value and evidence teams behind leading therapies Roche Bayer Takeda Sanofi Bristol Myers Squibb Moderna
Where the evidence stalls

Strong evidence does not fail. The format it travels in does.

A value dossier is written once, in one order, for a reader who does not exist: someone with the budget holder’s patience, the HTA reviewer’s appetite for methods, and the clinician’s interest in every subgroup.

So teams cut versions: the payer deck, the HTA submission summary, the P&T leave-behind. Every cut is another build and another review cycle, and the versions drift apart the moment the label moves. The alternative is one approved value story that holds every chapter, where the reader’s question decides the order. Nothing is duplicated, nothing drifts, and the rigor your HEOR team built stays intact in every route.

One figure, two desks

One budget-impact figure. Two readers. Two ways in.

Your value figure lands on the payer’s desk and on the medical lead’s desk in the same week. Tap a reader and watch their route through it change. Neither sits through the other’s part, and it is all one MLR review.

Your budget-impact value figureOne source. One review. One link.
The payer readerTheir route through the figure
1
2
3
Same figure, two reads, one review. Each route recombines chapters that were already approved, so nothing new is claimed and one MLR pass covers both journeys. The figure stops being a page in a dossier and becomes a way in for each desk.
The Impact Gap Report · 2026 FREE

Pharma keeps publishing. Physicians stopped reading.

60+ studies, side by side: why your best science never reaches the physicians it was written for, and what the evidence says actually works instead.

Get the free report →
57 pages · every number sourced · straight to your inbox
What makes this work

Three products, one job: make the evidence land.

This is not a video service bolted onto a dossier. Each product closes a specific gap between your evidence and the person deciding on it.

PubVisual Smart PathwaysThe lead for value stories

One approved value story. A route for every stakeholder.

Segmentation decides who receives the dossier. Smart Pathways decides what happens after they open it. The budget holder lands on budget impact, the HTA reviewer lands on methods, the clinician lands on outcomes, and every route recombines the same approved modules. No payer deck, no submission summary, no leave-behind drifting out of sync. One MLR review covers every journey, which is why personalization stops being rationed by compliance economics.

See PubVisual Smart Pathways →

The rigor survives the retelling.

Every chapter maps back to the dossier, the model, and the sources your HEOR team approved. Nothing is simplified into a different claim.

Zero new claimsEvery route recombines approved modules. Nothing appears that your team did not already write.
One source of truthWhen the data or the label moves, one update carries into every stakeholder’s route.
One coreFrom approved evidence to field-ready, moving through your review, not around it.
“The payer asked to keep the link. Nobody has ever asked to keep the dossier.”
Market Access Director · Respiratory
See it on your own evidence

Bring us your value story.

Send the dossier or the model. We will show you the chapters it becomes and the route each of your stakeholders would take through it. On the house. No promises.

Questions

Frequently asked questions

A video is one chapter of it. The product is a value story a stakeholder navigates: they choose the order, go as deep as they need, and take an approved next step where their interest peaks. The full dossier and the model stay one tap away for the reader who wants everything.

Nothing is simplified into a different claim. Every chapter maps to the dossier and sources your HEOR team approved. What changes is the order and the entry point, not the evidence, and the underlying detail stays available at full depth.

Yes. That is the Smart Pathways model: routes recombine approved modules, so the payer, the HTA reviewer, and the clinician each get their own way in while one review covers all of it. No versions to keep in sync.

It is built for them. The tone is evidence-first, every claim traces to an approved source, and the reader steers. Nothing pushes; the stakeholder chooses what to open next.

We will not tie it to a fixed date. You approve the core the normal way, at script, storyboard, and final animation. From there, that same approved core carries every version, so new cuts and languages do not restart the scientific review. The overall pace tracks your own review, which we plan around with you from day one.

Yes. Because every module maps to an approved claim, the whole story is structured for MLR from the first frame and fits your existing Veeva workflow.